Roxadustat for ESA‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review
ABSTRACT Anemia is the most common complication of end‐stage renal disease (ESRD). While erythropoiesis‐stimulating agents (ESA) have improved treatment outcomes, some patients exhibit intolerance or hyporesponsiveness. Roxadustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI), i...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2025-10-01
|
| Col·lecció: | Clinical Case Reports |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/ccr3.70985 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|